Michael Narachi

Michael Narachi is the current President & CEO of Coda Biotherapeutics. Prior to this, they served on the Board of Directors for PhRMA from April 2013 to April 2017. Michael also served as the President and CEO of Orexigen Therapeutics from March 2009 to August 2018, where they invented, developed and globally commercialized a novel weight loss therapeutic, Contrave. Prior to that, they were an Officer, Vice President and General Manager at Amgen from June 1984 to July 2004.

Michael Narachi earned their MS in Genetics and Molecular Biology from UC Davis and their MBA from the UCLA Anderson School of Management.

Annahita Keravala - SVP, Gene Therapy & Translation, Steven Dodson - SVP, Development & Pharmacology report to Michael Narachi.